Last updated 12 months ago
Quantitative Refractive Crosslinking in Presbyopia Aged Patients
25 patients around the world
Available in Brazil
The clinical trial is evaluating the TECLens CXLens Crosslinking System, an investigational treatment using ultraviolet (UV) light (375 nm) with riboflavin (vitamin B2) to strengthen and reshape the cornea. By creating controlled biomechanical changes, this study aims to test whether the cornea can be reshaped to reduce refractive errors such as mild myopia or hyperopia in patients of presbyopic age.
TECLens, Inc.
1Research sites
25Patients around the world
This study is for people with
Eye Diseases
Presbyopia
Requirements for the patient
To 65 Years
All Gender
Medical requirements
- Adults aged 40-65 years.Healthy cornea.Refractive error between +4.0 D and -5.0 D.Phakic or monofocal pseudophakic (≥6 months post IOL placement).Visual acuity correctable by ±0.25 D.
- Corneal dystrophy, scarring, or prior corneal crosslinking.Astigmatism >1.0 D.Active ocular infection, inflammation, or uncontrolled dry eye.Advanced glaucoma or diabetic retinopathy.History of delayed corneal healing.Pregnancy, breastfeeding, or planning pregnancy during study period.Certain medications (e.g., isotretinoin).Recent participation in other investigational drug/device studies (within 30 days).Patients with uncontrolled dry eye or surface disease.
Sites
Rio Vision - Hospital oftalmológico
SponsorTECLens, Inc.
Study typeInterventional
Conditions
Presbyopia
Requirements
To 65 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07137767
